What a New MRI Meta-Analysis Reveals About AI-Powered Hippocampal Segmentation and Alzheimer’s Disease

AriBio Co., Ltd. and Fujirebio Diagnostics, Inc. Announce Completion of Sample Set for the Strategic Partnership Implemented to Advance Biomarker Development for Alzheimer’s Disease and Neurodegeneration

SAN DIEGO & TOKYO & MALVERN, Pa.–(BUSINESS WIRE)–Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective sample acquisition as part of the strategic partnership to advance the development of biomarkers for Alzheimer’s disease and other neurodegenerative conditions. This milestone marks the fulfillment of AriBio’s commitment to provide plasma and matched cere…

What a New MRI Meta-Analysis Reveals About AI-Powered Hippocampal Segmentation and Alzheimer’s Disease

While AI-enabled hippocampal segmentation on MRI offered a 95 percent AUC for differentiating between Alzheimer’s disease and normal controls in a 27-study meta-analysis, it offered significantly lower sensitivity and specificity in differentiating mild cognitive impairment.